Literature DB >> 24599531

Serodiagnosis as adjunct assay for pertussis infection in São Paulo, Brazil.

Lourdes R A Vaz-de-Lima1, Monte D Martin, Lucia C Pawloski, Daniela Leite, Karen C P Rocha, Cyro A de Brito, Tânia M I Vaz, Luciano Moura Martins, Danielly P Alvarenga, Ana F Ribeiro, Telma R M P Carvalhanas, Rosa M D Nakasaki, Silvia S Oliveira, Eliseu A Waldman, Maria Lucia Tondella.   

Abstract

Pertussis remains an important public health problem in many countries despite extensive immunization. Cultures and real-time PCR (RT-PCR) assays are the recommended pertussis diagnostic tests, but they lack sensitivity at the later stage of the disease. This study introduces the IgG anti-pertussis toxin enzyme-linked immunosorbent assay (PT ELISA) in our routine diagnosis to improve disease burden estimation. Serum samples and nasopharyngeal swabs (n = 503) were collected at the same time from patients presenting with cough illness suspected of being pertussis and tested by the PT ELISA and culture and/or RT-PCR, respectively. Patients were separated into three age groups: group 1, <1 year (n = 260; mean age, 3 months), group 2, 1 to 6 years (n = 81; mean age, 3 years), and group 3, ≥7 years (n = 162; mean age, 26 years). The times (means) from cough onset to specimen collection were 16, 24, and 26 days, respectively. In group 1, 83 (82.2%) of 101 positive cases were positive for pertussis by culture/RT-PCR, while 40 (39.6%) tested positive by PT ELISA. In group 2, 6 (19.4%) of 31 positive cases were culture/RT-PCR positive, and 29 (93.6%) were seropositive. In group 3, 13 (13.8%) of 94 positive cases were positive by culture/RT-PCR and 91 (96.8%) were positive by serology. Culture/RT-PCR detected more cases of pertussis in infants (P < 0.0001), whereas the PT ELISA detected more cases in adolescents and adults (P < 0.0001). The timing between cough onset and specimen collection or recent vaccination may have partially affected our results. Serology is a suitable, cost-effective, and complementary pertussis diagnostic tool, especially among older children, adolescents, and adults during the later disease phase.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24599531      PMCID: PMC4018893          DOI: 10.1128/CVI.00760-13

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  23 in total

1.  Pertussis Pseudo-outbreak linked to specimens contaminated by Bordetella pertussis DNA From clinic surfaces.

Authors:  Sema Mandal; Kathleen M Tatti; Denise Woods-Stout; Pamela K Cassiday; Amanda E Faulkner; Matthew M Griffith; Michael L Jackson; Lucia C Pawloski; Bari Wagner; Meghan Barnes; Amanda C Cohn; Ken A Gershman; Nancy E Messonnier; Thomas A Clark; Maria-Lucia C Tondella; Stacey W Martin
Journal:  Pediatrics       Date:  2012-01-16       Impact factor: 7.124

2.  Antibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccine.

Authors:  Tine Dalby; Jesper Westphal Petersen; Zitta B Harboe; Karen Angeliki Krogfelt
Journal:  J Med Microbiol       Date:  2010-05-27       Impact factor: 2.472

3.  Development and analytical validation of an immunoassay for quantifying serum anti-pertussis toxin antibodies resulting from Bordetella pertussis infection.

Authors:  Sandra L Menzies; Vijay Kadwad; Lucia C Pawloski; Tsai-Lien Lin; Andrew L Baughman; Monte Martin; Maria Lucia C Tondella; Bruce D Meade
Journal:  Clin Vaccine Immunol       Date:  2009-10-28

4.  Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis.

Authors:  Stanley C Wei; Kathleen Tatti; Kimberly Cushing; Jennifer Rosen; Kristin Brown; Pamela Cassiday; Thomas Clark; Richard Olans; Lucia Pawloski; Monte Martin; Maria Lucia Tondella; Stacey W Martin
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

5.  Comparative study of different sources of pertussis toxin (PT) as coating antigens in IgG anti-PT enzyme-linked immunosorbent assays.

Authors:  Aditi Kapasi; Bruce D Meade; Brian Plikaytis; Lucia Pawloski; Monte D Martin; Sandra Yoder; Michael T Rock; Séverine Coddens; Valérie Haezebroeck; Françoise Fievet-Groyne; Garvin Bixler; Charles Jones; Stephen Hildreth; Kathryn M Edwards; Nancy E Messonnier; Maria L Tondella
Journal:  Clin Vaccine Immunol       Date:  2011-11-23

6.  Prospective evaluation of an Australian pertussis toxin IgG and IgA enzyme immunoassay.

Authors:  Meryta L May; Suhail A Doi; David King; Jenny Evans; Jennifer M Robson
Journal:  Clin Vaccine Immunol       Date:  2011-11-30

7.  Development and evaluation of dual-target real-time polymerase chain reaction assays to detect Bordetella spp.

Authors:  Kathleen M Tatti; Kai-Hui Wu; Maria Lucia Tondella; Pamela K Cassiday; Margaret M Cortese; Patricia P Wilkins; Gary N Sanden
Journal:  Diagn Microbiol Infect Dis       Date:  2008-04-25       Impact factor: 2.803

8.  Characterization of reference materials for human antiserum to pertussis antigens by an international collaborative study.

Authors:  Dorothy Xing; Carl Heinz Wirsing von König; Penny Newland; Marion Riffelmann; Bruce D Meade; Michael Corbel; Rose Gaines-Das
Journal:  Clin Vaccine Immunol       Date:  2008-12-24

Review 9.  What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories.

Authors:  N Guiso; G Berbers; N K Fry; Q He; M Riffelmann; C H Wirsing von König
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-11-11       Impact factor: 3.267

Review 10.  What is new in pertussis?

Authors:  Ellen S Bamberger; Isaac Srugo
Journal:  Eur J Pediatr       Date:  2007-08-01       Impact factor: 3.183

View more
  6 in total

Review 1.  Immune persistence after pertussis vaccination.

Authors:  Zhiyun Chen; Qiushui He
Journal:  Hum Vaccin Immunother       Date:  2017-01-03       Impact factor: 3.452

2.  Evaluation of Commercial Assays for Single-Point Diagnosis of Pertussis in the US.

Authors:  Lucia C Pawloski; Brian D Plikaytis; Monte D Martin; Stacey W Martin; Harry E Prince; Mary Lapé-Nixon; M Lucia Tondella
Journal:  J Pediatric Infect Dis Soc       Date:  2017-09-01       Impact factor: 3.164

3.  Clinical evaluation and validation of laboratory methods for the diagnosis of Bordetella pertussis infection: Culture, polymerase chain reaction (PCR) and anti-pertussis toxin IgG serology (IgG-PT).

Authors:  Adria D Lee; Pamela K Cassiday; Lucia C Pawloski; Kathleen M Tatti; Monte D Martin; Elizabeth C Briere; M Lucia Tondella; Stacey W Martin
Journal:  PLoS One       Date:  2018-04-13       Impact factor: 3.240

4.  SEVERE PERTUSSIS IN CHILDHOOD: UPDATE AND CONTROVERSY - SYSTEMATIC REVIEW.

Authors:  Márcia Borges Machado; Saulo Duarte Passos
Journal:  Rev Paul Pediatr       Date:  2019-06-19

5.  Expanding Pertussis Epidemiology in 6 Latin America Countries through the Latin American Pertussis Project.

Authors:  Veronica A Pinell-McNamara; Anna M Acosta; Maria Cristina Pedreira; Ana F Carvalho; Lucia Pawloski; Maria Lucia Tondella; Elizabeth Briere
Journal:  Emerg Infect Dis       Date:  2017-12       Impact factor: 6.883

6.  The burden of laboratory-confirmed pertussis in low- and middle-income countries since the inception of the Expanded Programme on Immunisation (EPI) in 1974: a systematic review and meta-analysis.

Authors:  Rudzani Muloiwa; Benjamin M Kagina; Mark E Engel; Gregory D Hussey
Journal:  BMC Med       Date:  2020-08-28       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.